Researchers at the University of California, Berkeley, and City of Hope, a cancer research organization in California, have introduced MechanoAge, a pioneering AI platform designed to evaluate breast cancer risk at the cellular level. Published in *Lancet’s eBioMedicine*, this innovative microfluidic platform analyzes individual breast epithelial cells by measuring their deformation, recovery, and behavior under stress. This method addresses a significant gap in risk assessment for the over 90% of women who lack known genetic predispositions or family histories of breast cancer. Mark LaBarge, a professor at City of Hope, emphasized that this tool provides tangible data for women to discuss with their doctors, moving beyond mere risk estimates. The MechanoAge platform employs a machine learning algorithm to quantify breast cancer risk by identifying signs of accelerated aging in cells. Notably, the platform is built using simple and affordable electronics, making it highly scalable compared to existing methods that rely on expensive imaging technologies. The research also uncovered that breast cells possess a 'mechanical age' that is distinct from chronological age, with older mechanical ages indicating a higher risk for breast cancer. This study represents a significant advancement in cancer research, showcasing the potential of interdisciplinary collaboration between engineering and biology.